<DOC>
	<DOCNO>NCT00887341</DOCNO>
	<brief_summary>This 2 arm study compare incidence tocilizumab-related infusion reaction , use 2 different infusion time , patient moderate severe rheumatoid arthritis show inadequate response DMARDs ( Disease Modifying Anti Rheumatic Drugs ) anti-TNFs.Patients randomize one 2 group , receive tocilizumab 8mg/kg iv every 4 week either ) 1h infusion time administration b ) 1h infusion time first administration , follow 31 minute infusion time subsequent administration ( unless drug-related infusion reaction occur ) .The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Comparing Infusion Rates Tocilizumab Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; active moderate severe rheumatoid arthritis ; active disease &gt; 6 month ; inadequate response stable dose nonbiologic DMARDs antiTNFs . rheumatic autoimmune disease rheumatoid arthritis ; prior history , current inflammatory joint disease rheumatoid arthritis ; major surgery ( include joint surgery ) within 8 week prior screen , plan major surgery within 6 month follow enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>